参考文献/References:
[1] Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med, 2012,2(8):1-18.
[2] Flowers SA, Rebeck GW. APOE in the normal brain. Neurobiol Dis, 2020,136:104724
[3] Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysisof 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet, 2013,45(12):1452-1458.
[4] Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 1993,261(5123): 921-923.
[5] Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer’s disease with apoE epsilon 2. Lancet, 1994, 343(8910): 1432-1433.
[6] Morris JC, Roe CM, Xiong C, et al. APOE Predicts Aβ but not Tau Alzheimer’s Pathology in Cognitively Normal Aging. Ann
Neurol, 2010, 67(1): 122-131.
[7] Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. Sci Transl Med, 2011, 3(89):89ra57.
[8] Friedman G, Froom P, Sazbon L, et al. Apolipoprotein E- ε4 genotype predicts a poor outcome in survivors of traumatic brain
injury. Neurology, 1999, 52(2):244-248.
[9] Egensperger R, K?sel S, von Eitzen U,et al. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol, 1998, 8(3):439-447.
[10] Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol, 2013, 70(4):440-444.
[11] Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet, 2017，390(10113):2673-2734.
[12] Bredesen DE, Amos EC, Canick J, et al. Reversal of cognitive decline in Alzheimer’s disease. Aging (Albany NY) ,8(6): 1250-1258.
[13] Lim AS, Yu L, Kowgier M, et al. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol, 70(12), 1544-1551.
[14] Freund Levi Y, Vedin I, Cederholm T,et al. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study. J Intern Med,2014, 275(4), 428-436.
[15] Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci, 27(16):4385-4395.
[16] Pifferi F, Roux F, Langelier B, et al. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J Nutr, 135(9): 2241-2246.
[17] Pifferi F, Jouin M, Alessandri JM, et al. n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukot Essent Fatty Acids, 2007, 77(5-6),279-286.
[18] Morris MC, Brockman J, Schneider JA, et al. Association of seafood consumption, brain mercury level, and APOE ε4 status with brain neuropathology in older adults. JAMA, 2016, 315(5)489-497.
[19] Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a Medical Food in Mild Alzheimer’s Disease: A Randomized,Controlled Trial. Alzheimers Dement. J. Alzheimers Dement,2010, 6(1):1-10.
[20] Kamphuis PJ, Verhey FR, Olde Rikkert MG, et al. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging, 2011, 15(8), 720-724.
[21] Avallone R, Vitale G, Bertolotti M. Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. Int J Mol Sci, 2019, 20(17), 4256-4278.
[22] Külzow N, Witte AV, Kerti L, et al. Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults. J Alzheimers Dis, 2016 51(3): 713-725.
[23] Yassine HN, Braskie MN, Mack WJ, et al. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol,2017,74(3):339-347.
[24] Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology, 2007,69(20):1921-1930.
[25] Stonehouse W, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr, 2013,97(5):1134-1143.
[26] Vellas B, Voisin T, Dufouil C, et al. MAPT (Multi-Domain Alzheimer’s Prevention Trial): clinical biomarkers, results and lessons for the future. J Prev Alzheimers Dis, 2015,2(4):292.
[27] van de Rest O, Geleijnse JM, Kok FJ, et al., Effect of fish oil on cognitive performance in older subjects: a randomized , controlled trial . Neurology, 2008, 71(6): 430-438.
[28] Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA, 304(17): 1903-1911.
[29] Yassine HN, Rawat V, Mack WJ, et al. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease. Alzheimers Res Ther,2016,8:25.
[30] Vandal M, Alata W, Tremblay C, et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem, 2014, 129(3), 516-526.
[31] Patrick RP. Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer’s disease. FASEB J, 2019, 33(2):1554-1564.
[32] Spector AA. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci,2001,16(2-3):159-165.
[33] Frayn KN, Summers LK, Fielding BA. Regulation of the plasma non-esterified fatty acid concentration in the postprandial state.Proc Nutr Soc, 1997,56(2):713-721.
[34] Lagarde M, Bernoud N, Brossard N, et al. Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci, 16(2-3):201-204.
[35] Liu L, Bartke N, Van Daele H, et al. Higher efficacy of dietary DHA provided as a phospholipid than as a triglyceride for brain DHA accretion in neonatal piglets. J Lipid Res, 2014, 55(3),531-539.
[36] Lagarde M, Hachem M, Bernoud-Hubac N, et al. Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain. Prostaglandins Leukot. Essent Fatty Acids, 2015, 92:63-65.
[37] Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.Arch. Neurol, 2006, 63(11):1545-1550.
[38] Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med, 2014, 20(4):415-418.
[39] Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron, 2015, 85
(2), 296-302.
[40] Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron, 2017, 94(3):581-594.
[41] Burri L, Hoem N, Banni S, et al. Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci, 2012, 13(11):
15401-15419.
[42] Dyerberg J, Madsen P, M?ller JM, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids, 2010, 83(3):137-141.
[43] Lemaitre-Delaunay D, Pachiaudi C, Laville M, et al. Blood compartmental metabolism of docosahexaenoic acid (DHA) in
humans after ingestion of a single dose of [13C]DHA in phosphatidylcholine. J Lipid Res,1999, 40(10):1867-1874.
[44] Brossard N, Croset M, Normand S, et al. Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood
cells. J Lipid Res, 38(8):1571-1582.
[45] Kitson AP, Metherel AH, Chen CT, et al. Effect of dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion. J Nutr Biochem, 2016, 33:91-102.
[46] Sugasini D, Thomas R, Yalagala PCR, et al. Dietary docosahexae‐noic acid (DHA) as lysophosphatidylcholine, but not as free acid,
enriches brain DHA and improves memory in adult mice. Sci Rep, 2017,7(1):11263.